Suppr超能文献

开发和验证一种用于指导高级消化道神经内分泌肿瘤决策的预后列线图。

Development and Validation of a Prognostic Nomogram to Guide Decision-Making for High-Grade Digestive Neuroendocrine Neoplasms.

机构信息

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.

出版信息

Oncologist. 2020 Apr;25(4):e659-e667. doi: 10.1634/theoncologist.2019-0566. Epub 2019 Nov 29.

Abstract

BACKGROUND

The objective of this study was to develop and validate a nomogram to predict 1-year overall survival (OS) and 2-year OS in patients with high-grade digestive neuroendocrine neoplasms (NENs) as well as to guide selection of subgroups that could benefit from systemic chemotherapy.

SUBJECTS, MATERIALS, AND METHODS: We performed a retrospective analysis of 223 patients with NENs of the gut and hepato-biliary-pancreatic system from four centers included in the development cohort. The nomogram was externally validated in a cohort of 90 patients from another one.

RESULTS

The final model included lactate dehydrogenase, performance status, stage, Ki67, and site of primary tumor, all of which had a significant effect on OS. The uncorrected C-index was 0.761 for OS, and the bias-corrected C-index was 0.744. Predictions correlated well with observed 1-year and 2-year outcomes (judged by eye). The area under the time-dependent receiver operating characteristic curve at 12 months and 24 months was 0.876 and 0.838, respectively. The nomogram performed well in terms of both discrimination and calibration when applied to the validation cohort, and OS was significantly different between the two groups classified by nomogram score (log-rank p < .001).

CONCLUSION

The validated nomogram provided useful prediction of OS, which can be offered for clinicians to improve their abilities to assess patient prognosis, to create clinical risk groups for informing treatment or for patient stratification by disease severity in clinical trials.

IMPLICATIONS FOR PRACTICE

The high-grade neuroendocrine neoplasms of the digestive system are rare malignancies with great heterogeneity. An overall survival nomogram was developed and externally validated in this study. Two subgroups were classified by the nomogram score, and platinum-based chemotherapy may not bring clinical benefit for the low-risk patients.

摘要

背景

本研究旨在开发并验证一个列线图,以预测高级消化系统神经内分泌肿瘤(NENs)患者的 1 年总生存(OS)和 2 年 OS,并指导选择可能从系统化疗中获益的亚组。

材料和方法

我们对来自四个中心的 223 名肠道和肝胆胰腺系统 NENs 患者进行了回顾性分析,这些患者纳入了开发队列。该列线图在另一个中心的 90 名患者的队列中进行了外部验证。

结果

最终模型包括乳酸脱氢酶、表现状态、分期、Ki67 和原发肿瘤部位,这些因素均对 OS 有显著影响。OS 的未校正 C 指数为 0.761,校正后 C 指数为 0.744。预测结果与观察到的 1 年和 2 年结果(目测判断)高度相关。12 个月和 24 个月时的时间依赖性接收者操作特征曲线下面积分别为 0.876 和 0.838。该列线图在验证队列中的判别和校准方面表现良好,根据列线图评分分类的两组之间的 OS 差异有统计学意义(对数秩检验 p<0.001)。

结论

验证的列线图对 OS 提供了有用的预测,可为临床医生提供帮助,以提高其评估患者预后的能力,为治疗提供临床风险分组,或为临床试验中根据疾病严重程度对患者进行分层。

实践意义

消化系统的高级神经内分泌肿瘤是一种罕见的具有高度异质性的恶性肿瘤。本研究开发并验证了一个总生存列线图。根据列线图评分将患者分为两个亚组,对于低风险患者,铂类化疗可能无法带来临床获益。

相似文献

引用本文的文献

5
A novel prognostic model for patients with colon adenocarcinoma.一种用于结直肠腺癌患者的新型预后模型。
Front Endocrinol (Lausanne). 2023 Feb 27;14:1133554. doi: 10.3389/fendo.2023.1133554. eCollection 2023.

本文引用的文献

2
Gastroenteropancreatic Neuroendocrine Tumors.胃肠胰神经内分泌肿瘤。
CA Cancer J Clin. 2018 Nov;68(6):471-487. doi: 10.3322/caac.21493. Epub 2018 Oct 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验